Dale Conaway
Directeur/Membre du Conseil chez BIOXYTRAN, INC.
Fortune : 109 526 $ au 31/05/2024
Profil
Dale H.
Conaway is an Independent Director at BioXyTran, Inc. and the Chief Veterinary Medical Officer at the Office of Research Oversight.
He previously served as a Director at Galectin Therapeutics, Inc., Avanyx Therapeutics, Inc., Boston Therapeutics, Inc., and BioXyTran, Inc. He also held the position of Manager-Equine Drug Testing & Animal Disease at the Michigan Department of Agriculture and worked as a Medical Officer-Veterinary at Federal Research, Inc. Dr. Conaway received a graduate degree from Michigan State University in 1984 and a doctorate degree from Tuskegee University in 1979.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOXYTRAN, INC.
0,54% | 19/04/2024 | 936 122 ( 0,54% ) | 109 526 $ | 31/05/2024 |
Postes actifs de Dale Conaway
| Sociétés | Poste | Début |
|---|---|---|
| BIOXYTRAN, INC. | Directeur/Membre du Conseil | 02/11/2018 |
| Office of Research Oversight | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Dale Conaway
| Sociétés | Poste | Fin |
|---|---|---|
Oxygen Therapy, Inc.
 Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Directeur/Membre du Conseil | 03/08/2018 |
| NANOMIX CORPORATION | Directeur/Membre du Conseil | 15/09/2016 |
Avanyx Therapeutics, Inc.
 Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Directeur/Membre du Conseil | 30/11/2010 |
| GALECTIN THERAPEUTICS INC. | Directeur/Membre du Conseil | 12/02/2009 |
| Federal Research, Inc. | Corporate Officer/Principal | 02/01/2006 |
Formation de Dale Conaway
| Tuskegee University | Doctorate Degree |
| Michigan State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| BIOXYTRAN, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
| Michigan Department of Agriculture | Government |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Office of Research Oversight | |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
 BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
| Federal Research, Inc. |
